Irbesartan Eg (Irbesartan)

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows the progression of kidney damage in type‑2 diabetes.
• Chronic kidney disease with hypertension: helps control blood pressure and proteinuria, supporting renal preservation.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding. This inhibition leads to vasodilation, reduced aldosterone secretion, decreased sodium and water retention, and ultimately lower systemic vascular resistance and blood pressure.

Irbesartan may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Nasal congestion: stuffy or runny nose.
• Hyperkalemia: elevated blood potassium levels.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat.
• Acute renal failure: sudden loss of kidney function.
• Severe hyperkalemia: dangerously high potassium that may affect heart rhythm.
• Hepatic injury: signs of liver dysfunction such as jaundice.
• Myocardial infarction: rare reports of heart attack.
• Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant parameters.

• Blood pressure monitoring: check regularly to avoid hypotension.
• Renal function: assess serum creatinine and eGFR before and during treatment.
• Electrolytes: monitor potassium levels, especially in patients on potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with liver disease.
• Pregnancy: avoid use; teratogenic risk is unknown.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Irbesartan can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use may increase renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia.
• ACE inhibitors: additive effect on potassium and renal function.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance hypotensive effect.
• Cyclosporine: can increase serum irbesartan levels.
• Rifampin: may reduce irbesartan concentrations.
• Digoxin: monitor for signs of toxicity as plasma levels may rise.